Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysa… (NCT05528705) | Clinical Trial Compass
CompletedNot Applicable
Investigator Initiated Trial to Evaluate Efficacy and Safety of LAENNEC (Human Placenta Hydrolysate) Administered by Ultrasonography Guided Subacromial Bursa Injection in Patients With Shoulder Impingement Syndrome
South Korea50 participantsStarted 2022-09-13
Plain-language summary
To patients with shoulder collision syndrome, LAENNEC (Human Placenta Hydrolysate) is administered as an injection in the ultrasonic induction underglone, to evaluate the effectiveness and safety.
Who can participate
Age range20 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. At the time of screening, 19 or 70 years
✓. Those who are suspected of rotator cuff lesions or damage due to shoulder pain
✓. Those who are judged to have a shoulder joint disease during screening
✓. Neer test, Hawkins-Kennedy inspection, job test, Painful Arc inspection or resisted showder external rotation test
✓. Those with a significant pain of 30 mm of Visual Analogue Scale (VAS)
✓. Those who can sign a test subject or to comply with the matters required for clinical trials.
Exclusion criteria
✕. A person who appears in the movement of two or more shoulder joints with more than 50% of the joint movement limit on the passive shoulder joint operation scope test.
✕. Those who have confirmed the rupture of the entire layer by ultrasound
✕. Those with serious damage to the shoulders and the past power
✕. Those who have suspected fractures, dislocations, degenerative arthritis, and calcification in the shoulder radiation test in the shoulder radiation test.
✕. Those who complain of shoulder pain due to stroke, spinal cord injury, and other surgery
✕. Those with other shoulder diseases other than fifty dogs (rheumatoid arthritis, osteoarthritis, bone defect injuries, malignant tumors, etc.)